New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival in Common Abdominal Infection of Liver Disease

New Analysis Confirms Albumin Preserves Kidney Function and Improves Survival
                in Common Abdominal Infection of Liver Disease

PR Newswire

KING OF PRUSSIA, Pa., Jan. 21, 2013

KING OF PRUSSIA, Pa., Jan. 21, 2013 /PRNewswire/ --Treatment with albumin
reduces renal impairment and mortality in cirrhotic patients with spontaneous
bacterial peritonitis (SBP), one of the most common bacterial infections in
this patient population, according to a new meta-analysis supported by CSL
Behring and published today in Clinical Gastroenterology and Hepatology, the
official clinical practice journal of the American Gastroenterological
Association Institute. Albumin, a natural plasma-derived protein that expands
blood plasma volume, is widely used in conjunction with large-volume
paracentesis to treat tense ascites, with vasoconstrictors for type 1
hepatorenal syndrome and with antibiotics for SBP.

"While current clinical guidelines indicate the benefits of albumin for
patients with SBP, questions regarding patient selection and albumin dosing in
the management of the condition still linger," said Francesco Salerno, M.D.,
Professor of Internal Medicine at the University of Milan in Italy, and lead
author of the meta-analysis. "Based on our quantitative findings and the clear
benefits demonstrated, it seems prudent to treat all SBP patients with
albumin, regardless of whether they are high-risk or low-risk for poor
outcome."

SBP occurs without any obvious source of intra-abdominal infection. Several
factors are believed to contribute to SBP including bacterial overgrowth in
the intestine, passage of the bacteria across an impaired intestinal barrier
into the blood stream and abdominal cavity, and a deficient local immune
response to the invasion. Renal impairment, a frequent complication of SBP, is
associated with high risk of mortality, which may reach 30% despite prompt
treatment.

The meta-analysis, which included results from four randomized controlled
trials with 288 total patients, found that SBP patients treated with albumin
were less likely to develop renal impairment (8.3 percent in the
albumin-treated groups versus 30.6 percent in the control groups). The odds
ratios for renal impairment in the four trials were highly consistent, ranging
from 0.19 to 0.30. The analysis also found that mortality was decreased with
albumin administration (16 percent in the albumin-treated groups versus 35.4
percent in the control groups). Odds ratios for mortality were also similar,
ranging from 0.16 to 0.55.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring is a subsidiary of CSL Limited (ASX:
CSL), a biopharmaceutical company with headquarters in Melbourne, Australia.
For more information visit http://www.cslbehring.com. CSL Behring operates one
of the world's largest plasma collection networks, CSL Plasma.

Contact:
Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
610-878-4209 (o)
484-919-2618 (c)
Sheila.Burke@cslbehring.com

SOURCE CSL Behring

Website: http://www.cslbehring.com